- Home
- VIVS vs AQMS Comparison
VIVS vs AQMS Comparison
Compare VIVS & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- AQMS
- Stock Information
- Founded
- VIVS 2007
- AQMS 2014
- Country
- VIVS United States
- AQMS United States
- Employees
- VIVS N/A
- AQMS N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- AQMS Metal Fabrications
- Sector
- VIVS Health Care
- AQMS Industrials
- Exchange
- VIVS Nasdaq
- AQMS Nasdaq
- Market Cap
- VIVS 4.7M
- AQMS 5.1M
- IPO Year
- VIVS N/A
- AQMS 2015
- Fundamental
- Price
- VIVS $3.64
- AQMS $3.96
- Analyst Decision
- VIVS
- AQMS Buy
- Analyst Count
- VIVS 0
- AQMS 1
- Target Price
- VIVS N/A
- AQMS $30.00
- AVG Volume (30 Days)
- VIVS 868.7K
- AQMS 38.3K
- Earning Date
- VIVS 11-07-2025
- AQMS 11-13-2025
- Dividend Yield
- VIVS N/A
- AQMS N/A
- EPS Growth
- VIVS N/A
- AQMS N/A
- EPS
- VIVS N/A
- AQMS N/A
- Revenue
- VIVS $142,000.00
- AQMS N/A
- Revenue This Year
- VIVS $42.38
- AQMS N/A
- Revenue Next Year
- VIVS $15.42
- AQMS $550.00
- P/E Ratio
- VIVS N/A
- AQMS N/A
- Revenue Growth
- VIVS 94.52
- AQMS N/A
- 52 Week Low
- VIVS $1.41
- AQMS $3.37
- 52 Week High
- VIVS $21.96
- AQMS $46.00
- Technical
- Relative Strength Index (RSI)
- VIVS 62.00
- AQMS 49.77
- Support Level
- VIVS $3.29
- AQMS $3.56
- Resistance Level
- VIVS $5.30
- AQMS $4.30
- Average True Range (ATR)
- VIVS 0.63
- AQMS 0.31
- MACD
- VIVS 0.16
- AQMS 0.08
- Stochastic Oscillator
- VIVS 52.16
- AQMS 51.25
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.